Based upon the above-mentioned biological and clinical characteristics, especially their homogeneous mutation pattern in AML patients, NPM1 mutations may be considered an ideal leukemia-specific target for MRD detection [2]. This evidence concerns the gene NPM1 and acute myeloid leukemia.